Venus Concept Inc. (VERO) Earnings
VERO has beaten EPS estimates in 1 of its last 12 reported quarters (average surprise -63.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Nov 13, 2025 | $-3.61 | $-12.14 | -236.3% | $14M | -4.9% |
| Aug 14, 2025 | $-9.72 | $-8.03 | +17.4% | $16M | +8.4% |
| May 15, 2025 | $-14.08 | $-17.44 | -23.9% | $14M | -6.5% |
| Mar 31, 2025 | $-10.01 | $-11.23 | -12.2% | $16M | +12.6% |
| May 15, 2024 | $-1.53 | $-18.48 | -1107.8% | $17M | +2.9% |
| Nov 14, 2023 | $-1.51 | $-18.04 | -1094.7% | $18M | -21.5% |
| Aug 14, 2023 | $-1.54 | $-14.85 | -864.3% | $20M | -2.9% |
| May 15, 2023 | $-2.12 | $-20.35 | -859.9% | $21M | +10.5% |
| Nov 10, 2022 | $-19.79 | $-36.29 | -83.4% | $22M | -2.7% |
| Aug 12, 2022 | $-13.19 | $-26.39 | -100.1% | $27M | -9.9% |
| May 12, 2022 | $-16.49 | $-21.44 | -30.0% | $26M | -2.3% |
| Nov 12, 2021 | $-21.44 | $-29.69 | -38.5% | $25M | -22.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q3 FY2025 · November 13, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Q3 saw 2% growth in EBD sales year-over-year driven by strong execution in a challenging environment, with stabilization in EBD revenue trends noted. - On November 10, Venus Nova received 510 clearance, a next-generation multi-application platform redefining noninvasive treatments, with U.S. commercial introduction expected to contribute to long-term growth, targeting sequential growth in Q4 with limited commercial launch of Venus Nova in December. - Balance sheet and capital structure transformation in Q3 included amendments to increase financing capacity under bridge loan facility and $11.5 million debt-to-equity exchange transactions. - Pending sale of Venus Hair to MHG Co. Ltd. faced challenges with counterparty, and assistance from Delaware court sought, but continued pursuit of closing the transaction. - Product portfolio evolving to focus on total practice performance from clinic entry to post-treatment management.
Guidance
- Targeting sequential growth in the fourth quarter, fueled in part by limited commercial launch of Venus Nova in December. - The company is not providing full-year 2025 financial guidance at this time due to active dialogue with lenders and investors and current market conditions.
Segment performance
Total revenue for the third quarter was $13.8 million, down high single digits year over year. Revenue from energy-based devices (EBD) increased 2% year over year to $9.5 million. EBD sales exclude system sales from the Venus Hair Restoration business. The percent of total systems revenue derived from internal lease programs was approximately 27% in 2025 compared to 23% in the prior year period. Cash sales represented approximately 73% of total systems and subscription revenue in the third quarter, with cash sales in the U.S. being 82% of U.S. systems and subscription revenue compared to 76% last year.
Risks & headwinds
- Challenges with counterparty in closing the sale of Venus Hair to MHG Co. Ltd., requiring Delaware court assistance. - Customer financing pressures, economic uncertainty, and tight credit markets impacting robotic system adoption in Venus Hair business. - Impact of U.S. tariffs on devices imported into the U.S. market affecting gross margin. - Higher device system cost of goods sold due to manufacturing overheads spread over lower volume base.
Analyst Q&A
Q:
A:
Q:
A: